Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain  by Chekhonin, Vladimir P. et al.
Volume 287, number I ,2, 149-152 FEBS 10001 
1991 Federation of European Biochemical Societie, 00155793/91/$3.50 
ADOh’lS 001357939100722L 
August 1991 
Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins 
as carriers for neuroleptic targeted delivery in brain 
Vladimir P. Chekhonin’, Alexander V. Kabanov2, Yurii A. Zhirkov’ and Georgii V. Morozov’ 
’ V.P. Serbsky All-Union Research Institute for General and Forensic Psychiatry, Kropotkinskiiper. 23, Moscow 119839 and =All- 
Union Research Center of Molecular Diagnostics and Therapy, Simpheropolskii blvd. 8, Moscow 113149, USSR 
Received 27 May 199 1 
A method for targeted delivery of neuroleptics from blood in brain based on using Fab-fragments of antibodies to antigens of brain glia cells 
(acid gliofibrillar antigen and a,-glycoprotein) is suggested. The essence of the technique is that the molecule of neuroleptic (trifluoperazine) is conju- 
gated with Fab-fragments of these antibodies. The conjugate thus obtained is modified by stearoylchloride in the system of Aerosol OT reversed 
micelles in octane. The study of the distribution of lZSI-labelled conjugates in the rat organism after intrdcordial introduction is performed. On 
the contrary to the nonmodified conjugates and conjugate, containing fatty acylated Fab-fragments of antibodies, nonspecific to the rat brain, 
the conjugate of trifluoperarine with stearoylated Fab-fragments of antibodies to neurospecific antigens accumulate in brain tissues. The drastic 
increase of the neuroleptic activity of trifluoperazine resulting from its coupling with stearoylated Fab-fragments of antiglial antibodies is observed. 
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1. INTRODUCTION 
The problem of transporting low and high molecular 
weight biologically active substances through the 
blood-brain barrier (BBB) into the brain is of great in- 
terest to medicine. Low permeability of the barrier with 
respect to nonpolar substances considerably restricts 
possibilities of application of antibiotics (and other 
drugs) during the therapy of tumours and brain 
regional infections, as well as the use of neuroleptics 
during psychiatric diseases, etc. [l-3]. Therefore, it is 
little wonder that many laboratories are engaged in the 
active search for ways of drug targeting through the 
BBB [3-61. In particular, we have recently developed a 
method for directed delivery in the brain of neuroleptic, 
based on incorporation of the latter in microcontainers 
formed by the micelles of a polymeric surfactant, 
presumably capable of transcytosis through the BBB 
[5]. Here we describe another method for neuroleptic- 
targeted delivery in the brain glia cells using the Fab- 
fragments of antibodies to the antigens of glia cells [4]. 
The essence of this technique is that the molecule of a 
neuroleptic is conjugated with Fab-fragments of these 
/lhbrevictfrons; Aerosol OT, AOT, sodium bis(2-ethylhexyl)sulfosuc- 
cinate; GFA, acid gliofibrillar antigen; ~wGP, ul-glycoprotein; tri- 
fluopcrazine,stelarine, 10.[3-(4.methylpiperazinLyl)-propyll-2-(tri- 
fluoromethyl)-lOWphcnothia7ine; TNBS, 2,4,6_trinitrobenzenesul- 
fonic acid 
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antibodies. In order to enhance the efficiency of the 
transport of the thus obtained conjugate into the brain, 
Fab-fragments are chemically modified by fatty acid 
residues. It was reported recently that attachment of a 
hydrophobe to a protein molecule via its artificial fatty 
acylation results in an increase in protein binding with 
a cell membrane and, at least in some cases, in enhance- 
ment of protein penetration within the cell [7]. 
In this paper we demonstrate the possibility of 
targeted delivery from the blood to the brain of 
trifluoperazine conjugated with fatty acylated Fab- 
fragments of rabbit polyclonal antibodies against 
human acid gliofibrillar antigen (GFA) (81 and human 
brain ocz-glycoprotein (a*-GP) [9]. 
2. MATERIALS AND METHODS 
Antisera against human brain GF.4, (u:-GP, and CY- and 
<ul-globulins were obtained from chinchilla rabbits immunized with 
purified preparations of these antigens [S-IO]. Specific antibodies 
were separated by immunosorption using the antigens immobilized on 
the CNBr-activated Sepharose 4B (Pharmacia) [I 11. F(ab)z and Fab- 
fragments were prepared from rhe purified antibodies by limited pro- 
teolysis with bocine trypsin (Sigma) as described elsewhere [4,12]. 
2.2, Epo~ylriSluoroperozrrle synthesis 
In order to synthesize the epoxytrifluoroperazine, further used for 
conjugation with antibody Fab-fragments, the trifluoroperarine 
molecule was modified by epichlorhydrin. This reaction (quaterniza- 
tion of the tertiary nitrogen in the neuroleptic piperazine ring) was 
conducted in alkalized aqueous ethanol (pH 9.6) at 40°C during 4 h. 
The exces, of epichlorhydrin and the major Dart of the SOlvent were 
evaporated. Epoxytrifluoroperazine was precipi[ated from ethyl 
acetate, di\,olved in water and lyophilized. The presence of the epoxy 
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;I tiigh cross-reactivity with the corresponding proteins 
from t hc rat bl-ain (data not shok\ n). At the came time 
the irnmunoflLlorescence study, performed using the 
cuts of various rat or-gans, re\,ealed that these an 
[ibodies sclwtivelq inreractcd only \vith brain tiwies 
(data nor 4io\vn). 
The Fab-fragments of antibodies to ~LIIIKI~ 011 alld 
t~z-globulins, which re~ealecl no cro$s-reactivity wirh 
the car-l-espo~~ling rat proteins, \scrc used as Fah- 
fragment\ lioti~pe~ifi~ to ra?t brain tissue. 
Tfx covalent binding of the drug to the Fab- 
fragment\ of’ antibociiec \zar achieved through a reac- 
tive epoxy group which \\as inserted in the 
trifluoperazine molecule as described above. U’e sup- 
pose that the conjugation proceeds preferentiaIly 
through a reaction bct\veen epoxy grsups of the 
modified dr~~g and free amino groups of a protein. Ac- 
cording IO the tirration data of free amino groups by 
TNM, each Fab-fragment in the conjugate obtained 
\~a5 linked \z.ith 5-10 trifluoptrarine molecules. The at- 
tachment of the lll~~~iifie~~ Iriflllo~~era~,~~~e did not in- 
fluence the imlllunosi7ceifit~ of the ~a~~-fra~rnet~ts since 
rhe conjugates preser\cd their ability to interact \+ith 
specific immunosorbents. Only those corljugate frac- 
tions which wet-e additionall!, purified by an im- 
munororption on the columns \sith immobilized an- 
tigens, have been used throughout all esperiments 
described below 
Introduction of a hydrophobe in the biopolymel 
molecule was proposed for increasing biopolgmer bin- 
ding with cell membranes [IX] and cnhan~ement of its 
~~i(er~~~~ii~a~ion in the ceil [7,19]. In order to modify rhc 
conjugates \\,.i;ith ste~tro~l~tlloI-i~ie w  used the recently 
dcvelopcd method for protein, ril~~d~fi~ation n-ith \vntcr 
insoluhlc reagents in the \y\lem of izerosol OT reversed 
micclie~ in octane [ 141. According to the TNBS titration 
data thus obtained, stearoylated colijupates contained 
from I to 3 fatty acid Iresidue per protein molcCule. 
uic have studied the effect 01‘ fatty acylation on the 
distribution in the rat organism of inrracordially ad- 
ministered tr,ifluoperazine-Fab-fraglncnt conjugates. 
As can be seen in Fis. I, the cx~njugatea nonmodified 
with stearoyl residues containin, ~7 Fab-fragments both 
specific and nonspecific to the proteins of rat brain are 
detected mostly in blood, liver. spleen and kidneys. 
~~o~lifi~aIioI1 of Fab-f.r~~~nle~l~ wnjugates by fatty acid 
residues leads I0 3 considerable decrease in their content 
in blood. Three days after aciministrntiorl of fatty 
acylatod nonspecific Fab-fragments conjugate it ac- 
cumulate mostly in the liver. This c‘an be explained b> 
the presence in Ihe li\er of larse amounts of a fatty acid 
binding protein [20]. Quite another phenomenon is 
observed in the case of fat0 acylatcd conjugates, con- 
taining Fab-fragmenls of antibodies specifi< to rat 
brain thal acwmulate mostly in brain tissues (Fig. 1). 
(Their localization index in the brain is masimal at the 
third day after ~tdntirtisrration.) 
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Fig. I. Distribution of ‘“‘I-labelled nonmodified and stearoylated 
conjugates containing Fab-fragments of nonspecific and brain tissue 
specific antibodies, in the rat organism at the 3rd day after intracor- 
dial administration. 
What is the reason for the observed effect of targeted 
f~ff~z~~~u~t of fatty acylatcd conjugates into the brain? 
Interaction of Fab-fragments of antibodies with GFA 
and a+3P-antigens located in brain glial cells [8,9] is 
only possible after penetration of the former through 
the BBB. At the same time, it should be taken into con- 
sideration that we used polyclonal antibodies that are 
probably capable of interacting with antigens located 
on the external side of the BBB (e.g. in the sites of en- 
dothelial cell contacts). In this case the effective ac- 
cumulation of the fatty acylated conjugates in the brain 
may be the result of the presence in their molecules of 
two sites of binding with BBB membranes, namely, the 
hydrophobic anchor and the antigen recognizing site. 
Introduction of the fatty acid residue in this case results 
in enhancement of conjugate binding with the mem- 
branes (including these of BBB) which in its turn pro- 
vides for increase in the apparent constant of Fab- 
fragment binding with the antigen. 
In any case the observed phenomena are of great in- 
terest in the development of systems for drug targeting 
into the brain. The results of the evaluation of the 
biological activity of the trifluoperazine and its con- 
j ugates with Fab-fragments of antibodies to 
neurospecific proteins are presented in Table 1. These 
results are compared with data from animals treated 
with the same protein preparations not conjugated with 
the drug. It is obvious that the last preparations are not 
toxic for rats and did not cause any symptoms of 
neurolepsy. In contrast, for the fatty acylated con- 
jugates, a drastic increase in toxicity associated with 
typical neuroleptic symptoms is observed. This effect 
cannot be explained by increased toxicity of the 
modified drug itself since the applied method of 
chemical modification does not essentially alter the 
biological activity of the trifluoperazine (data not 
shown). 
The data obtained indicate that the conjugates of 
neuroleptics with fatty acylated Fab-fragments of an- 
tibodies to neurospecific proteins are capable of 
penetrating through the BBB and reaching biological 
targets of the brain. lt is highfy probable that the 
transfer of fatty acylated Fab-fragment conjugate 
across BBB is accomplished via transcytosis 1211. 
We assume, that the use of fatty acylated Fab- 
fragments of antibodies to neurospecific proteins opens 
perspectives for creating principally new drugs for the 
therapy of various brain diseases. 
Table I 
Neuroleptic activity of trifluoperazinc and it.4 conjugates with Fab-fragments of antibodies against neurospecific antigens after intracordiai ad- 
ministration in rat 
Compound ‘“lO(l (mg/kg body weight) Symptoms of neurolepsy* 
1 2 3 4 
_._...._ 
‘frifluoperarine 10 ++++ ++++ -t+++ t+++ 
Conjugate of trifluoperazine with stearoylated Fab-fragments 0.025** +t t+ ++t+ -t -c + t + +++ 
Conjugate of trifluoperazine uith nonmodified Fab-fragments 25** t t+ -t + +t 
Stearoylated Fab-fragments non-toxic 
Nonmodified F&fragments non-toxic 
* 1 --= Closing symptom: 2 = extremity traction symptom; 3 = extrapyramidal disorders; 4 = convulsions. 
**The conjugate concentration is presented. 
1.51 
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